Related Experiment Video
Updated: Apr 17, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial
Ted M Getz1, Jan Philipp Bewersdorf1
1Section of Hematology, Department of Internal Medicine, Yale University and Yale Comprehensive Cancer Center, New Haven, CT 06520, USA.
Resistance to isocitrate dehydrogenase (IDH) inhibitors poses a significant challenge in acute myeloid leukemia (AML), indicating a need for novel IDH inhibitors. Hu et al. report the results of a phase 1 study of the dual IDH1/2 inhibitor HMPL-306 in relapsed/refractory IDH-mutant AML.1 The study highlights its manageable safety profile and robust preliminary efficacy, suggesting that it may be a valuable AML therapy.
Resistance to isocitrate dehydrogenase (IDH) inhibitors poses a significant challenge in acute myeloid leukemia (AML), indicating a need for novel IDH inhibitors. Hu et al. report the results of a phase 1 study of the dual IDH1/2 inhibitor HMPL-306 in relapsed/refractory IDH-mutant AML.1 The study highlights its manageable safety profile and robust preliminary efficacy, suggesting that it may be a valuable AML therapy.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Preclinical Development: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Study Design: Healthy Subjects Versus Patients

